Altogether, these data highlight that 12- and 5-LOX inhibitors with antioxidant properties, like NDGA, could be efficiently used for targeting simultaneously critical pathological mechanisms in cancer such as proliferation, defective apoptosis, metastasis and angiogenesis, as well as the chronically enhanced oxidative stress in the tumor niche. This evidence concerns the gene LOX and cancer.